Quick Detail:
Product name | Letrozole |
Other name | Femara |
CAS register number | 112809-51-5 |
Molecular formula | C17H11N5 |
Molecular weight | 285.3 |
Molecular structure | ![]() |
Assay | 99% |
Appearance | White Powder |
Usage | Used as API in Treatment of breast disease. |
Standard | Enterprise standard/ ISO9001 |
Price | Negotiated |
Minimum order quantity | 10g |
Package: | Exquisite and can according to customers’ requirement |
Shipping leading time | Within 24 hours after receiving the payment |
Payment options | Western Union, MoneyGram, bank transfer, Bitcoin |
Shipping |
1)Express delivery with DHL,EMS,Fedex,HKEMS,TNT,UPS(within 5-7days after payment) 2)By sea (large quantity ,it will take 30-45days) |
Keywords:
Letrozole ;Femara ; Letrozol ,SERM
Letrozole Antiestrogen / Hormone anticarcinogen
Femara Anabolic effect enhancer
Letrozol Strengthening Anabolic steroid
Femara for sale
Femara price
Femara UK
Letrozole 5mg
Description:
1. Letrozole is an oral non-steroidal inhibitor for the treatment of hormonally-responsive breast cancer after surgery.
2. Letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome p450 unit, the action is specific,and letrozol does not reduce production of mineralo-or corticosteroids.
3. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
4. Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years.
Applications:
Femara(generic name is letrozole) is a new drug developed for the treatment of advanced breast cancer in women. Femara is the second in a new class of third-generation selective oral aromatase inhibitors.
It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen. Since many forms of breast cancer cells are stimulated by estrogen, it is hoped that by reducing amounts of estrogen in the body the progression of such a disease can be halted. This is the basic premise behind Nolvadex, except this drug blocks the action and not production of estrogen.
The effects of Femara can be quite dramatic to say the least. A daily dose of one tablet (2.5 mg) can produce estrogen suppression greater than 80 % in treated patients. With the powerful effect this drug has on hormone levels, it is only to be used (clinically) by post-menopausal women whose disease has progressed following treatment with Nolvadex. Side effects like hot flushes and hair thinning can be present, and would no doubt be much more severe in pre-menopausal patients.
When used with strong, readily aromatizing androgens such as Dianabol or testosterone, gynecomastia and water retention can be effectively blocked. In combination with Propecia (finasteride), we have a great advance.
With the one drug halting estrogen conversion and the other blocking 5-alpha reduction (testosterone, methyltestosterone and Halotestin only), related side effects can be effectively minimized. Here the strong androgen testosterone could theoretically provide incredible muscular growth, while at the same time being as tolerable as nandrolone.
Additionally the quality of the muscle should be greater, the athlete appearing harder and much more defined without holding excess water.
Specifications:
Tests | Specifications | Results |
Appearance | White or off-white crystaline powder |
White Crystalline powder |
Solubility
|
Soluble in Chloroform; Soluble in ethanol when heated |
Conform |
ldentification |
(1)Maximum absorption in wavelength of 240 nm Minimum absorption in wavelength of 215 nm |
Conform Conform |
(2)Infrared spectrum should be in accordance the dominant peak of contrast | In accordance with the dominant peak of contrast | |
Melting points | 182℃-184℃ | 182℃ |
Related substances | ≤0.5% | 0.3% |
Single impurity | ≤0.3% | 0.2% |
Loss on drying | ≤1.0% | 0.8% |
[Assay]C17H11N5 (On anhydrous basis) |
≥98.0% | 99.2% |
Conclusion | Conforms Specifications of Enterprise Standard. |